BLAINJECTIONINJECTABLEPriority Review
Approved
Jun 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
COLUMVI (glofitamab) by Roche is cd20-directed antibody interactions [moa]. Approved for bispecific cd20-directed cd3 t cell engager [epc]. First approved in 2023.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COLUMVI (glofitamab) is a bispecific CD20-directed CD3 T cell engager approved June 2023 for relapsed/refractory B-cell non-Hodgkin lymphoma. It works by simultaneously binding CD20 on tumor B cells and CD3 on T cells, redirecting immune cells to kill cancer. This novel mechanism represents a shift from traditional monoclonal antibodies to engineered bispecific antibodies.
Growth
Early-stage growth product with moderate competitive pressure (30%) indicates expanding team investment in field sales, medical liaisons, and market access roles.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
Bispecific CD20-directed CD3 T Cell Engager
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Started Dec 2026
40 enrolled
Relapsed /Refractory DLBCL
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Started Nov 2026
30 enrolled
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLymphoma+1 more
Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics
Started Sep 2026
16 enrolled
Relapsed/Refractory Diffuse Large B-cell LymphomaRelapsed/Refractory Mantle Cell Lymphoma
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
Started Jun 2026
41 enrolled
Mantle Cell Lymphoma
Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas
Started Apr 2026
40 enrolled
Diffuse Large B Cell Lymphoma Refractory
Worked on COLUMVI at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.